In SLE, positive serology, leukopenia, lymphopenia, anemia, and thrombocytopenia have been well described

In SLE, positive serology, leukopenia, lymphopenia, anemia, and thrombocytopenia have been well described. Within 1 week of initiation of treatment with steroids and mycophenolate mofetil, Ehrlichia chaffeensis titers (IgM Benzyl chloroformate and IgG) were undetectable and Benzyl chloroformate titers to EBV IgM and IgG decreased (0.49 and 6.83AU/ml, respectively). IgM titers for EpsteinBarr computer virus and human granulocytic ehrlichiosis were negative. Human granulocytic ehrlichiosis screening was also unfavorable. In the presence of multiple positive serologies, laboratory data, and some clinical features, the patient was presumptively treated for ehrlichiosis with a 14-day course of doxycycline. At a 4-week follow up, repeat Ehrlichia chaffeensis IgM and IgG titers were further elevated (1:1024 and 1:2048, respectively) and retreatment with minocycline was initiated. Due to drug intolerance the patient discontinued the treatment. A urinalysis revealed 3+ protein; 24 h urine protein measured 0.6 gm/day and in the following week increased to 1.7 gm/day. A renal biopsy was performed. What is the renal biopsy likely to show? == The Diagnosis Class IV-G(A) lupus nephritis == Further clinical decline occurred and over the subsequent 2-week period, Benzyl chloroformate her presentation met the American College of Rheumatology criteria for any definitive diagnosis of systemic lupus erythematosus (SLE) (positive antinuclear antibody, positive anti-double-stranded DNA, malar rash, proteinuria, leukopenia, thrombocytopenia, and psychosis). Renal biopsy (Physique 1) revealed diffuse proliferative lupus nephritis (ISN/RPS Class IV-G(A)) with activity index 10/24 and chronicity index 0/12 according to the National Institutes of Health criteria. Focal evidence of lupus vasculopathy was recognized. == Physique 1. == Renal biopsy showing diffuse proliferative lupus nephritis (ISN/RPS Class IV-G(A)) with focal evidence of lupus vasculopathy. Ehrlichiosis CHK1 and SLE have comparable features. Symptoms of ehrlichiosis include severe headache, myalgias, and fever. Confusion may also occur. Nausea, vomiting, Benzyl chloroformate and abdominal pain are uncommon and moderate. Symptoms of SLE include fever, malaise, anorexia, fatigue, weight loss, myalgias, photosensitivity, alopecia. Cognitive dysfunction, headache, mood disorder, cerebrovascular disease, seizures, polyneuropathy, stress, and psychosis may also occur. On exam, patients with ehrlichiosis display a maculopapular rash and hepatomegaly. Lymphadenopathy is observed in less than 25%. Malar rash or discoid rash and symmetrical oligoarticular arthritis are seen in SLE. Lymphadenopathy is frequently observed; however generalized lymphadenopathy is usually rare. Laboratory findings in ehrlichiosis include positive serology, thrombocytopenia, and disseminated intravascular coagulation (in severe ehrlichiosis). In SLE, positive serology, leukopenia, lymphopenia, anemia, and thrombocytopenia have been well explained. Within 1 week of initiation of treatment with steroids and mycophenolate mofetil, Ehrlichia chaffeensis titers (IgM and IgG) were undetectable and titers to EBV IgM and IgG decreased (0.49 and 6.83 AU/ml, respectively). Within several weeks the patient’s SLE joined remission. This case statement illustrates the importance of realizing false-positive antibody titers in the presence of active SLE.1In Benzyl chloroformate addition to Ehrlichia, false-positive antibodies to the following infectious etiologies have been reported in patients with SLE: syphilis, Lyme disease,2hepatitis C,3HIV,4cytomegalovirus,1and the severe acute respiratory syndrome virus.5To our knowledge, this is the first reported association of false-positive Ehrlichia species antibodies in patients with SLE. == Recommendations ==.